Windtree Therapeutics Stock EBITDA

WINT Stock

USD 0.50 0.01 1.96%

Windtree Therapeutics fundamentals help investors to digest information that contributes to Windtree Therapeutics' financial success or failures. It also enables traders to predict the movement of Windtree Stock. The fundamental analysis module provides a way to measure Windtree Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Windtree Therapeutics stock.

		Last Reported	Projected for Next Year
	EBITDA	-20.2 M	-21.2 M

EBITDA is likely to drop to about (21.2 M) in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Windtree Therapeutics Company EBITDA Analysis

Windtree Therapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Windtree Therapeutics EBITDA

(20.16 M)

Most of Windtree Therapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Windtree Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Windtree EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for Windtree Therapeutics is extremely important. It helps to project a fair market value of Windtree Stock properly, considering its historical fundamentals such as EBITDA. Since Windtree Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Windtree Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Windtree Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Current Deferred Revenue	Long Term Debt	Treasury Stock	Property Plant Equipment	Net Receivables	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Short Long Term Debt	Deferred Long Term Liab	Net Invested Capital	Net Working Capital	Good Will	Capital Stock	Intangible Assets
Total Assets		0.96	-0.46	-0.36	0.21	0.73	0.45	-0.26	-0.32	-0.17	0.0	-0.34	-0.06	0.29	0.33	0.18	0.49	-0.47	0.57	0.84	0.69	0.18	0.11	0.09
Total Stockholder Equity	0.96		-0.59	-0.15	0.07	0.52	0.5	-0.44	-0.15	-0.15	-0.16	-0.18	-0.04	0.08	0.41	0.02	0.34	-0.43	0.49	0.77	0.63	0.26	0.18	0.13
Net Debt	-0.46	-0.59		-0.23	0.1	-0.03	-0.91	0.51	0.11	-0.12	-0.1	0.17	-0.04	0.12	-0.65	-0.13	0.24	-0.07	0.21	0.02	0.03	-0.41	-0.35	-0.27
Retained Earnings	-0.36	-0.15	-0.23		-0.13	-0.64	0.14	-0.11	0.76	-0.08	-0.02	0.71	-0.51	-0.9	0.26	-0.05	-0.86	0.61	-0.71	-0.47	-0.6	0.53	0.55	0.62
Accounts Payable	0.21	0.07	0.1	-0.13		0.55	0.13	0.44	-0.34	0.21	0.58	-0.37	-0.57	0.28	0.16	0.6	0.04	0.41	-0.14	0.14	-0.12	0.37	0.43	0.45
Total Liab	0.73	0.52	-0.03	-0.64	0.55		0.22	0.31	-0.59	-0.11	0.46	-0.6	-0.12	0.61	0.03	0.57	0.66	-0.29	0.49	0.67	0.52	0.12	0.06	0.04
Total Current Assets	0.45	0.5	-0.91	0.14	0.13	0.22		-0.3	-0.22	0.04	0.46	-0.26	-0.12	0.04	0.73	0.45	-0.19	0.17	-0.28	-0.1	-0.17	0.38	0.37	0.33
Short Term Debt	-0.26	-0.44	0.51	-0.11	0.44	0.31	-0.3		-0.14	0.04	0.52	-0.16	-0.37	0.15	-0.35	0.46	0.01	0.37	-0.21	-0.11	-0.21	0.21	0.2	0.23
Common Stock	-0.32	-0.15	0.11	0.76	-0.34	-0.59	-0.22	-0.14		-0.57	-0.26	0.99	-0.32	-0.94	-0.01	-0.28	-0.43	0.23	-0.25	-0.21	-0.23	0.14	0.15	0.16
Current Deferred Revenue	-0.17	-0.15	-0.12	-0.08	0.21	-0.11	0.04	0.04	-0.57		-0.07	-0.59	0.14	0.37	0.03	-0.1	-0.27	0.3	-0.27	-0.22	-0.24	0.15	0.16	0.17
Long Term Debt	0.0	-0.16	-0.1	-0.02	0.58	0.46	0.46	0.52	-0.26	-0.07		-0.3	-0.47	0.22	0.23	0.92	-0.13	0.44	-0.45	-0.28	-0.43	0.35	0.39	0.42
Treasury Stock	-0.34	-0.18	0.17	0.71	-0.37	-0.6	-0.26	-0.16	0.99	-0.59	-0.3		-0.27	-0.9	-0.03	-0.32	-0.37	0.19	-0.2	-0.21	-0.21	0.04	0.07	0.08
Property Plant Equipment	-0.06	-0.04	-0.04	-0.51	-0.57	-0.12	-0.12	-0.37	-0.32	0.14	-0.47	-0.27		0.35	-0.11	-0.58	0.44	-0.51	0.5	0.04	0.37	-0.57	-0.69	-0.85
Net Receivables	0.29	0.08	0.12	-0.9	0.28	0.61	0.04	0.15	-0.94	0.37	0.22	-0.9	0.35		-0.11	0.24	0.6	-0.41	0.42	0.27	0.32	-0.38	-0.34	-0.35
Net Tangible Assets	0.33	0.41	-0.65	0.26	0.16	0.03	0.73	-0.35	-0.01	0.03	0.23	-0.03	-0.11	-0.11		0.14	-0.26	0.15	-0.17	-0.07	-0.25	0.16	0.21	0.2
Long Term Debt Total	0.18	0.02	-0.13	-0.05	0.6	0.57	0.45	0.46	-0.28	-0.1	0.92	-0.32	-0.58	0.24	0.14		-0.04	0.33	-0.34	-0.08	-0.24	0.39	0.51	0.47
Capital Surpluse	0.49	0.34	0.24	-0.86	0.04	0.66	-0.19	0.01	-0.43	-0.27	-0.13	-0.37	0.44	0.6	-0.26	-0.04		-0.72	0.9	0.68	0.78	-0.49	-0.54	-0.64
Short Long Term Debt	-0.47	-0.43	-0.07	0.61	0.41	-0.29	0.17	0.37	0.23	0.3	0.44	0.19	-0.51	-0.41	0.15	0.33	-0.72		-0.81	-0.63	-0.75	0.49	0.52	0.58
Deferred Long Term Liab	0.57	0.49	0.21	-0.71	-0.14	0.49	-0.28	-0.21	-0.25	-0.27	-0.45	-0.2	0.5	0.42	-0.17	-0.34	0.9	-0.81		0.81	0.89	-0.51	-0.56	-0.66
Net Invested Capital	0.84	0.77	0.02	-0.47	0.14	0.67	-0.1	-0.11	-0.21	-0.22	-0.28	-0.21	0.04	0.27	-0.07	-0.08	0.68	-0.63	0.81		0.9	0.01	-0.06	-0.13
Net Working Capital	0.69	0.63	0.03	-0.6	-0.12	0.52	-0.17	-0.21	-0.23	-0.24	-0.43	-0.21	0.37	0.32	-0.25	-0.24	0.78	-0.75	0.89	0.9		-0.17	-0.25	-0.45
Good Will	0.18	0.26	-0.41	0.53	0.37	0.12	0.38	0.21	0.14	0.15	0.35	0.04	-0.57	-0.38	0.16	0.39	-0.49	0.49	-0.51	0.01	-0.17		0.9	0.82
Capital Stock	0.11	0.18	-0.35	0.55	0.43	0.06	0.37	0.2	0.15	0.16	0.39	0.07	-0.69	-0.34	0.21	0.51	-0.54	0.52	-0.56	-0.06	-0.25	0.9		0.8
Intangible Assets	0.09	0.13	-0.27	0.62	0.45	0.04	0.33	0.23	0.16	0.17	0.42	0.08	-0.85	-0.35	0.2	0.47	-0.64	0.58	-0.66	-0.13	-0.45	0.82	0.8

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict Windtree Therapeutics

Ebitda Over Time

Windtree Ebitda

Ebitda

(21.17 Million)

At this time, Windtree Therapeutics' EBITDA is comparatively stable compared to the past year.

According to the company disclosure, Windtree Therapeutics reported earnings before interest,tax, depreciation and amortization of (20.16 Million). This is 102.3% lower than that of the Biotechnology sector and 120.13% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.52% higher than that of the company.

Windtree EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Windtree Therapeutics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Windtree Therapeutics could also be used in its relative valuation, which is a method of valuing Windtree Therapeutics by comparing valuation metrics of similar companies.

Windtree Therapeutics is currently under evaluation in ebitda category among its peers.

Windtree Therapeutics Institutional Holders

Institutional Holdings refers to the ownership stake in Windtree Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Windtree Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Windtree Therapeutics' value.

		Shares
Tower Research Capital Llc	2024-06-30	1.5 K
Bank Of America Corp	2024-06-30	4.0
Ubs Group Ag	2024-06-30	3.0
Activest Wealth Management	2024-06-30	2.0
Ifp Advisors, Llc	2024-06-30	1.0

Windtree Fundamentals

	Return On Equity	-1.51
	Return On Asset	-0.45
	Current Valuation	5.97 M
	Shares Outstanding	8.75 M
	Shares Owned By Insiders	0.27 %
	Shares Owned By Institutions	0.59 %
	Number Of Shares Shorted	195.67 K
	Price To Earning	(0.05) X
	Price To Book	1.26 X
	Price To Sales	660.53 X
	Gross Profit	(17.79 M)
	EBITDA	(20.16 M)
	Net Income	(20.29 M)
	Cash And Equivalents	11.38 M
	Cash Per Share	0.37 X
	Total Debt	16.83 M
	Debt To Equity	0.95 %
	Current Ratio	2.47 X
	Book Value Per Share	5.90 X
	Cash Flow From Operations	(13.44 M)
	Short Ratio	0.06 X
	Earnings Per Share	(19.03) X
	Target Price	7.0
	Beta	0.64
	Market Capitalization	4.92 M
	Total Asset	32.41 M
	Retained Earnings	(844.82 M)
	Working Capital	1.38 M
	Current Asset	40.79 M
	Current Liabilities	11.07 M
	Net Asset	32.41 M

About Windtree Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Windtree Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Windtree Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Windtree Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Windtree Stock Analysis

When running Windtree Therapeutics' price analysis, check to measure Windtree Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Windtree Therapeutics is operating at the current time. Most of Windtree Therapeutics' value examination focuses on studying past and present price action to predict the probability of Windtree Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Windtree Therapeutics' price. Additionally, you may evaluate how the addition of Windtree Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC